VANCOUVER, British Columbia, Feb. 07, 2019 (GLOBE NEWSWIRE) — Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry, announced today as a part of its expansion plans, the Company is now formally entering the cannabis clinic space.
The recent acquisition of Cloud Practice has provided an underlying platform to help empower and streamline patient-doctor interaction. “We are currently working on a partnership model to hard code the decision-making process into the Electronic Medical Records (EMR),” said Dr. Essam Hamza, CEO of Premier. “There has been a critical gap between the patient’s need for medical cannabis and the doctor’s knowledge and comfort level in prescribing it. At Premier we understand the frustration felt from both the patient and the doctor and are integrating what we think is a revolutionary process. This new tool will allow us to provide a much-needed service to the 287 clinics and almost 3 million patients in our ecosystem.”
Much of the traditionally labor-intensive process of onboarding patients will now be done automatically with Premier’s smart EMR. The doctor will just need to identify patients with conditions that could warrant medical cannabis consideration and the integrated technology will assess the patient’s data, and through the use of analytics, output a comprehensive recommendation along with links to corresponding medical research specific to the diagnosis. Thus, providing essential education and guidance to doctors enabling them to make informed decisions on medical cannabis qualification, dosing and prescriptions.
Additionally, the Company has been in discussions with a short list of Canadian Licensed Producers (LP) under the Access to Cannabis for Medical Purposes Regulations (ACMPR) in order to partner with a, or multiple, LP(s) to provide doctor and patient education at the clinic level.
The company expects to provide additional updates on its expansion later in Q1 2019.
ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD”
Chief Executive Officer
About Premier Health
Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are developing innovative health care approaches that combine human skill-based expertise with emerging technologies, with the goal of setting the gold standard for services in locations of interest worldwide. Premier Health’s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally. The HealthVue team has a strong track record of successfully creating value in healthcare and technology enterprises. The Management team has deep clinical, financial and operational expertise and a passion for improving healthcare for all patients.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
FOR ADDITIONAL INFORMATION CONTACT:
Premier Health Group Inc.
DISCLAIMER: Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE
ParcelPal (PTNYF) (PKG) Continues National Expansion Strategy by Launching in Toronto, Ontario
VANCOUVER, British Columbia, July 18, 2019 /PRNewswire/ — ParcelPal Technology Inc. (“ParcelPal”), (PKG.CN) (PT0.F) (PTNYF) is pleased to announce that it plans to continue its national rollout to Ontario, aiming at Canada’sfinancial capital, Toronto, as its initial launching point.
ParcelPal has secured an office in Toronto, and is currently onboarding all key personnel to fill all necessary roles for the upcoming launch, which is expected to occur shortly. ParcelPal is also actively looking to expand with new and existing partnerships within this region.
ParcelPal’s mission is to exponentially grow its business by making mobile on-demand deliveries a common, widespread service throughout cities across Canada. The Company has been operating successfully in Vancouver, Calgary and Saskatoon and is now focusing its expansion plans in Ontario as part of its on-going strategy for Canada wide distribution. As the largest market in Canada, the Province of Ontario has over 14 million residents and represents a significant increase in the size of the markets currently being serviced by ParcelPal.
Following the announced partnership with Cowbell Brewing Co. (“Cowbell”) last month, ParcelPal plans to start servicing clients in Ontario starting with the Greater Toronto Area (“GTA”) and later rolling out to other cities within Ontario.
ParcelPal will be launching with all verticals offered (Food, alcohol, grocery, and ‘Get Anything’). ParcelPal is also in late stage planning for implementation of cannabis delivery in the province of Ontario. ParcelPal will make entry to strategic urban cities in the Province during its first and second phase of its rollout plan. This in turn will allow ParcelPal to continue its rapid growth whilst ensuring a superior customer experience as witnessed in other cities that are currently being serviced by ParcelPal.
President and CEO, Kelly Abbott states, “We are very pleased to be able to offer ParcelPal services to the residents of Toronto. Ontario is Canada’s largest province, and we are excited by the opportunity that it presents to us and our shareholders. We feel an expansion to Ontario will bring great value to our various stakeholders and with the up coming launch will be the cornerstone for all expansions moving forward. Our increased investments in technology, brand and delivery are on track to make our service even easier to use, whilst expanding our customer’s choices. I’m pleased with the strong results of the past year and excited by our opportunity for accelerated growth across Canada.”
Director and Chief strategy officer Peter Hinam states, “We have worked long and hard to achieve this important milestone in our company’s growth. We feel it will bring ParcelPal to the next level by offering our unequal service in Canada’s most populated city.”
About ParcelPal Technology Inc.
ParcelPal is a technology-driven logistics company that connects consumers to the goods they love. Customers can shop at partner businesses and through the ParcelPal technology receive their purchased goods within an hour. ParcelPal offers on-demand delivery of merchandise from leading retailers, restaurants, medical marijuana dispensaries and liquor stores in Vancouver and soon in major cities Canada-wide.
ParcelPal Website: www. parcelpal. com
The Canadian Securities Exchange (“CSE”) or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release that has been prepared by management.
CSE – Symbol: PKG
FSE – Symbol: PT0
OTC – Symbol: PTNYF
Forward Looking Information
We seek safe harbour
This news release contains forward looking statements relating to the Proposed Transaction, and the future potential of ParcelPal. Forward looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects”, “plans” and similar expressions. All statements other than statements of historical fact, included in this release are forward looking statements that involve risks and uncertainties. These risks and uncertainties include, without limitation, the risk that the Proposed Transaction will not be completed due to, among other things, failure to execute definitive documentation, failure to complete satisfactory due diligence, failure to receive the approval of the CSE and the risk that ParcelPal will not be successful due to, among other things, general risks relating to the mobile application industry, failure of ParcelPal to gain market acceptance and potential challenges to the intellectual property utilized in ParcelPal. There can be no assurance that any forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
ParcelPal cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and ParcelPal will only update or revise publicly any of the included forward looking statements as expressly required by Canadian securities laws.
peter@ parcelpal . com
PharmaCyte Biotech (PMCB) Appoints Cellular Expert to Medical and Scientific Advisory Board
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed David A. Judd to PharmaCyte’s Medical and Scientific Advisory Board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and methods for the culturing various types of human cells. Most importantly, Mr. Judd has worked for many years with the cells that PharmaCyte uses in its treatment of cancer and has a wealth of knowledge regarding their growth properties.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We feel the appointment of Mr. Judd to our Medical and Scientific Advisory Board comes at a crucial time as we work with our colleagues at Austrianova to conduct the final manufacturing runs to produce successfully the encapsulated cells that are needed for our clinical trial in locally advanced, non-metastatic, pancreatic cancer.”
Mr. Waggoner continued, “Mr. Judd was so intrigued by the possibility that our platform technology may change the way many solid tumors are treated, with little to no chemotherapy side effects, that he volunteered to work with us months ago. He has made significant contributions to our efforts in working with Austrianova to ensure that the cells from our Master Cell Bank grow as they should, both pre and post-encapsulation. During a critical time in realigning certain aspects of the manufacturing process, Mr. Judd accompanied us as an advisor to Austrianova’s cGMP manufacturing facility in Bangkok, Thailand, where the encapsulation of our cells is taking place.
“In a recent video interview, which can be viewed at www.PharmaCyte.com/Media, I spoke to why we selected Mr. Judd to join our team and the contributions he has already made to our Cancer Program. We believe that Mr. Judd’s talents and expertise will be invaluable in the development of cellular therapies for cancer as well as our efforts in the development of cellular therapies for diabetes.”
Mr. Judd is a graduate of the Biotechnology program at Rochester Institute of Technology, the first Biotechnology program in the United States. He has over 30 years of experience in cell culture and biochemistry in research and in a cGMP environment. Also, he has extensive experience in research and development of cell culture medium, both in the upstream and downstream processes.
Mr. Judd is currently employed by the Grand Island Biotechnology Company (Gibco) and is involved in research, process development and cGMP production of biotechnology and cell therapy processes.
Mr. Judd has been employed by Gibco (now owned by ThermoFischer Scientific) for 29 years and is a co-inventor on 5 patents involving cell culture materials.
About PharmaCyte Biotech:
PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.
PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.
Stock Price Monday Morning Update – July 15, 2019
List Of Biotech Stocks To Watch This Quarter
Biotech has been one of the hottest sectors for the past few years. Much of that is due to the fact that there are many biotech stocks doing highly innovative work.
3 Tech Stocks To Watch For July
For the past few decades, tech stocks have almost always been the most popular stocks in the market. Considering the sort of returns some of the tech giants have generated over decades, it doesn’t come as a surprise.
Gold Prices Have Investors Scrambling & Analysts Clamoring For Junior Gold Stocks
Gold has long been a safe haven stock. But as the market turned toward tech, precious metal stocks took a back seat…until now. Could the timing of gold’s next bull run be perfect right now?
Search Stock Price (StockPrice.com)
Sponsored Content1 month ago
Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market
Featured4 months ago
Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond
Cannabis3 months ago
Two Massive Growth Industries, One Choice for Investors
Biotechnology1 month ago
Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks
Featured1 month ago
This New Technology Could Transform A Multi-Billion-Dollar Industry!
Cannabis2 months ago
A New Cannabis Trend That The Market Should Take Immediate Notice Of Is Here!
Biotechnology2 weeks ago
The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company
Featured3 months ago
Opportunity Ahead for This Healthcare Stock